Table 3. Univariate analysis of overall survival.
VariableCategoriesHazard ratio95% CIP
Age class≥60 years10.6033
<60 years1.138(0.699–1.853)
Metastatic siteVisceral10.279
Visceral and bone0.883(0.526–1.481)
Bone0.457(0.175–1.194)
Number of metastatic sites1 Site10.5883
Multiple sites1.166(0.668–2.035)
Disease-free interval>12 months10.0767
≤12 months0.584(0.322–1.059)
Therapeutic settingThird line or more10.0128
Second line1.302(0.74–2.291)
First line0.456(0.231–0.9)
CTC status (EPISPOT assay)>0 CTC/mL10.0191
0 CTC/mL0.467(0.247–0.883)
CTC status (CellSearch assay)Positive10.0007
Negative0.386(0.223–0.668)
CTC status (CellSearch and EPISPOT assays)Double negative1
CellSearch7.582(1.646–34.923)0.0308
EPISPOT6.175(1.38–27.628)
CellSearch + EPISPOT8.732(2.053–37.132)
Menopausal statusPremenopausal1
Postmenopausal1.208(0.651–2.24)0.5492
HistologyOthers1
Lobular1.204(0.421–3.445)0.9339
Ductal1.141(0.518–2.516)
ER statusPositive1
Negative2.204(1.338–3.63)0.0019
PR statusPositive1
Negative1.537(0.945–2.501)0.0831
HER2 statusPositive1
Negative1.689(0.94–3.034)0.0794
SubtypeLuminal1
HER2 positive0.993(0.488–2.023)0.9853
Triple negative2.451(1.088–5.519)0.0304